Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity reiterates 'buy' on Jet2

(Sharecast News) - Analysts at Canaccord Genuity reiterated their 'buy' rating on package holidays business Jet2, noting that the group has been investing for a "high return future". Canaccord Genuity held its FY25 pre-tax profits estimate at £563m, 3% below consensus, and said it still sees a lower pre-tax profit margin year-on-year.

The Canadian bank sees downside risk to consensus FY26 pre-tax profits, noting that any reactionary share price weakness would be a buying opportunity to increase a position in Jet2 shares, which continue to trade on a price-to-earnings ratio of more than 30% below pre-Covid levels.

Canaccord noted that FY26 will see start-up costs at Luton and Bournemouth, £45.0m of external-driven labour-related and SAF cost increases, and 3% year-on-year wage increases, offset by fuel hedging and a more efficient fleet.

"We see PBT outlook almost unchanged - with PBT margin lower YoY but profits still up (2% YoY). To us, PBT growth potential despite external pressures continues to demonstrate Jet2's strengths, stemming from the value of holidays - which are >80% of Jet2's revenues - backed up by a 'Fortress Balance Sheet'," said Canaccord, which stood by its 2,050.0p target price on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.